Table 3.2 summarises the developments identified in Part 3 and shows the likely time frames in which these matters will need to be considered in a formal manner by the Jurisdictional Blood Committee and governments for their policy implications.
Issue | Potential for impact | Likely time frame |
---|---|---|
Transmissible diseases | High | Immediate and ongoing |
Testing and manufacturing | High | Medium to long |
Blood management techniques | Medium | Medium to long |
Patient safety | Low | Short to medium |
New products | High | Short to medium |
IVIg developments | High | Medium to long |
Development of substitutes for plasma-derived products | Medium | Medium to long |
New recombinant products | Medium | Medium |
Market structure | Low | Medium |
Research | Medium | Medium |
Inquiries and legal action | Low | Medium |